Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Ferlay, Hai-rim Shin, F. Bray, D. Forman, C. Mathers, D. Parkin (2010)Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
International Journal of Cancer, 127
H. Davies, E. Dicks, P. Stephens, Charles Cox, J. Teague, C. Greenman, G. Bignell, S. O'meara, S. Edkins, A. Parker, C. Stevens, A. Menzies, M. Blow, B. Bottomley, Mark Dronsfield, P. Futreal, Michael Stratton, R. Wooster (2006)High throughput DNA sequence variant detection by conformation sensitive capillary electrophoresis and automated peak comparison.
Genomics, 87 3
SM Sy, MS Huen, J Chen (2009)PALB2 is an integral component of the BRCA complex required for homologous recombination repair
Proc Natl Acad Sci USA, 106
C. Mehta, Nitin Patel (1983)A Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables
Journal of the American Statistical Association, 78
Fan Zhang, Q. Fan, Keqin Ren, P. Andreassen (2009)PALB2 Functionally Connects the Breast Cancer Susceptibility Proteins BRCA1 and BRCA2
Molecular Cancer Research, 7
David Tan, C. Marchiò, J. Reis-Filho (2008)Hereditary breast cancer: from molecular pathology to tailored therapies
Journal of Clinical Pathology, 61
C. Asperen, R. Brohet, E. Meijers-Heijboer, N. Hoogerbrugge, S. Verhoef, H. Vasen, M. Ausems, F. Menko, E. Garcia, J. Klijn, Frans Hogervorst, J. Houwelingen, L. Veer, M. Rookus, F. Leeuwen (2005)Cancer risks in BRCA2 families: estimates for sites other than breast and ovary
Journal of Medical Genetics, 42
B. Xia, Qing Sheng, K. Nakanishi, A. Ohashi, Jianmin Wu, N. Christ, Xinggang Liu, M. Jasin, F. Couch, D. Livingston (2006)Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.
Molecular cell, 22 6
M. Tischkowitz, B. Xia, N. Sabbaghian, J. Reis-Filho, N. Hamel, Guilan Li, E. Beers, Lili Li, T. Khalil, Louise Quenneville, A. Omeroglu, A. Poll, P. Lepage, N. Wong, P. Nederlof, A. Ashworth, P. Tonin, S. Narod, D. Livingston, W. Foulkes (2007)Analysis of PALB2/FANCN-associated breast cancer families
Proceedings of the National Academy of Sciences, 104
M. Tischkowitz, B. Xia (2010)PALB2/FANCN: recombining cancer and Fanconi anemia.
Cancer research, 70 19
M. Adank, S. Mil, Johan Gille, Q. Waisfisz, H. Meijers-Heijboer (2011)PALB2 analysis in BRCA2-like families
Breast Cancer Research and Treatment, 127
M. Tischkowitz, N. Sabbaghian, N. Hamel, A. Borgida, Chaim Rosner, Nassim Taherian, A. Srivastava, S. Holter, H. Rothenmund, P. Ghadirian, W. Foulkes, S. Gallinger (2009)Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer.
Gastroenterology, 137 3
M Tischkowitz, B Xia, N Sabbaghian (2007)Analysis of PALB2/FANCN-associated breast cancer families
Proc Natl Acad Sci, 104
N. Rahman, S. Seal, D. Thompson, P. Kelly, A. Renwick, Anna Elliott, S. Reid, Katarina Spanova, R. Barfoot, T. Chagtai, H. Jayatilake, L. McGuffog, S. Hanks, D. Evans, D. Eccles, D. Easton, Michael Stratton (2007)PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene
Nature Genetics, 39
T. Buchholz, D. Wazer (2002)Molecular biology and genetics of breast cancer development: a clinical perspective.
Seminars in radiation oncology, 12 4
C. Mehta, N. Patel (1983)A network algorithm for the exact treatment of Fisher's exact test in RxC contingency tables
E. Verna, C. Hwang, P. Stevens, H. Rotterdam, S. Stavropoulos, Carolyn Sy, M. Prince, W. Chung, R. Fine, J. Chabot, H. Frucht (2010)Pancreatic Cancer Screening in a Prospective Cohort of High-Risk Patients: A Comprehensive Strategy of Imaging and Genetics
Clinical Cancer Research, 16
(1999)Cancer risks in BRCA2 mutation carriers
J Natl Cancer Inst, 91
D Ford, DF Easton, M Stratton (1998)Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families
Amer J Hum Genet, 62
K. Hirshfield, T. Rebbeck, A. Levine (2010)Germline Mutations and Polymorphisms in the Origins of Cancers in Women
Journal of Oncology, 2010
E. Velasco, M. Infante, M. Durán, L. Pérez-Cabornero, D. Sanz, Eva Esteban-Cardeñosa, C. Miner (2007)Heteroduplex analysis by capillary array electrophoresis for rapid mutation detection in large multiexon genes
Nature Protocols, 2
Feng Zhang, Jianglin Ma, Jiaxue Wu, L. Ye, Hong Cai, B. Xia, Xiaochun Yu (2009)PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response
Current Biology, 19
D. Ford, D. Easton, Michael Stratton, S. Narod, D. Goldgar, P. Devilee, D. Bishop, B. Weber, G. Lenoir, J. Chang-Claude, H. Sobol, M. Teare, J. Struewing, A. Arason, S. Scherneck, J. Peto, T. Rebbeck, P. Tonin, S. Neuhausen, R. Barkardottir, J. Eyfjord, H. Lynch, B. Ponder, S. Gayther, J. Birch, A. Lindblom, D. Stoppa-Lyonnet, Y. Bignon, Å. Borg, U. Hamann, N. Haites, Rodney Scott, C. Maugard, H. Vasen, S. Seitz, L. Cannon-Albright, A. Schofield, M. Zelada-Hedman (1998)Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
American journal of human genetics, 62 3
S. Reid, D. Schindler, H. Hanenberg, K. Barker, S. Hanks, R. Kalb, K. Neveling, P. Kelly, S. Seal, M. Freund, M. Wurm, S. Batish, Francis Lach, S. Yetgin, H. Neitzel, H. Ariffin, M. Tischkowitz, C. Mathew, A. Auerbach, N. Rahman (2007)Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer
Nature Genetics, 39
G. Byrnes, M. Southey, J. Hopper (2008)Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories?
Breast Cancer Research : BCR, 10
T. Heikkinen, Hanni Kärkkäinen, Kirsimari Aaltonen, R. Milne, P. Heikkilä, K. Aittomäki, C. Blomqvist, H. Nevanlinna (2009)The Breast Cancer Susceptibility Mutation PALB2 1592delT Is Associated with an Aggressive Tumor Phenotype
Clinical Cancer Research, 15
T. Walsh, M. King (2007)Ten genes for inherited breast cancer.
Cancer cell, 11 2
E. Slater, P. Langer, E. Niemczyk, K. Strauch, J. Butler, N. Habbe, J. Neoptolemos, W. Greenhalf, D. Bartsch (2010)PALB2 mutations in European familial pancreatic cancer families
Clinical Genetics, 78
A. Oliver, S. Swift, C. Lord, A. Ashworth, L. Pearl (2009)Structural basis for recruitment of BRCA2 by PALB2
EMBO reports, 10
Shirley Sy, M. Huen, Junjie Chen (2009)PALB2 is an integral component of the BRCA complex required for homologous recombination repair
Proceedings of the National Academy of Sciences, 106
H. Olsson (1999)Cancer risks in BRCA2 mutation carriers.
Journal of the National Cancer Institute, 91 15
Siân Jones, R. Hruban, M. Kamiyama, Michael Borges, Xiaosong Zhang, D. Parsons, Jimmy Lin, Emily Palmisano, K. Brune, E. Jaffee, C. Iacobuzio-Donahue, A. Maitra, G. Parmigiani, S. Kern, V. Velculescu, K. Kinzler, B. Vogelstein, J. Eshleman, M. Goggins, A. Klein (2009)Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
PALB2 (Partner And Localizer of BRCA2) binds to and co-localizes with BRCA2 in DNA repair. Germline mutations in PALB2 have been identified in approximately 1–2% of familial breast cancer and 3–4% of familial pancreatic cancer cases. The goal of this study was to evaluate the prevalence of PALB2 mutations in women with breast cancer without BRCA1/2 mutations who also had a personal or family history of pancreatic cancer. PALB2 mutation analysis was performed in 94 non-BRCA1/2 breast cancer patients with a personal or family history of pancreatic cancer. Two truncating PALB2 mutations, c.3549C>CA and c.2962C>CT, were identified resulting in a mutation prevalence of 2.1%. The proband found to carry the c.3549C>CA PALB2 mutation had a mother diagnosed with both breast and pancreatic cancer; this relative was subsequently confirmed to carry the identical mutation. The proband with the c.2962C>CT mutation had a father and paternal aunt diagnosed with pancreatic cancer; neither relative was available for testing. Two novel PALB2 missense variants were also found, one of which was deemed potentially deleterious. The prevalence rate of PALB2 mutations in a non-BRCA1/2 breast cancer population specifically selected for a family history of pancreatic cancer does not appear to be significantly increased compared to that observed in other breast cancer populations studied thus far. Further evaluation is needed to determine the prevalence of PALB2 mutations and the clinical utility of such testing in those individuals affected with both breast and pancreatic cancers.
Familial Cancer – Springer Journals
Published: Mar 2, 2011
Access the full text.
Sign up today, get DeepDyve free for 14 days.